Vanguard Fiduciary Trust
KALV

Vanguard Fiduciary Trust’s KalVista Pharmaceuticals KALV Stock Holding History

Vanguard Fiduciary Trust’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-276,391
Closed -$5.56M – 4118
2026
Q1 		$5.56M Buy
+276,391
New +$4.45M ﹤0.01% 2019

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Fiduciary Trust's KALV Position: Q2 2026 in Review

Vanguard Fiduciary Trust sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 276,391 shares — an estimated $5.56M sold.

Vanguard Fiduciary Trust first reported a position in KALV in Q1 2026 and held it in 1 quarter. The position peaked at $5.56M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Vanguard Fiduciary Trust reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Fiduciary Trust sold 276,391 KalVista Pharmaceuticals shares in Q2 2026, an estimated $5.56M.
  • Vanguard Fiduciary Trust first reported a position in KalVista Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Fiduciary Trust's KalVista Pharmaceuticals position peaked at $5.56M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.